EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER
Contact:Charles ButlerVice President, Investor Relations and Corporate CommunicationsExelixis, Inc.(650) 837-7277cbutler@exelixis.com Anders EdvellVice President, Sobi Partner Products, Sobi+46 8 697 2000anders.edvell@sobi.com Jörgen WinrothVice President, Investor Relations, Sobi+46 8 697 3427jorgen.winroth@sobi.com South San Francisco, CA and Stockholm, Sweden - February 22, 2013 - Exelixis,Inc. (NASDAQ:EXEL) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) todayannounced that they have entered into a three-year agreement to support thedistribution and commercialization of